Literature DB >> 21671079

Increasing incidence of Barrett's oesophagus: a population-based study.

Helen G Coleman1, Shivaram Bhat, Liam J Murray, Damian McManus, Anna T Gavin, Brian T Johnston.   

Abstract

Oesophageal adenocarcinoma, a highly fatal cancer, has risen in incidence in Western societies, but it is unclear whether this is due to increasing incidence of its pre-cursor condition, Barrett's oesophagus (BO) or whether the proportion of BO patients undergoing malignant progression has increased in the face of unchanged BO incidence. Data from population-based studies of BO incidence is limited, with equivocal results to date difficult to distinguish from changes in endoscopic practices. The aim of this study was to assess population trends in Barrett's oesophagus (BO) diagnoses in relation to endoscopy and biopsy rates over a 13 year period. The Northern Ireland Barrett's oesophagus Register (NIBR) is a population-based register of all 9,329 adults diagnosed with columnar epithelium of the oesophagus in Northern Ireland between 1993 and 2005, of whom 58.3% were male. European age-standardised annual BO incidence rates were calculated per 100,000 of the population, per 100 endoscopies and per 100 endoscopies including an oesophageal biopsy. Average annual BO incidence rates rose by 159% during the study period, increasing from 23.9/100,000 during 1993-1997 to 62.0/100,000 during 2002-2005. This elevation far exceeded corresponding increases in rates of endoscopies and oesophageal biopsies being conducted. BO incidence increased most markedly in individuals aged < 60 years, and most notably amongst males aged < 40 years. This study points towards a true increase in the incidence of BO which would appear to be most marked in young males. These findings have significant implications for future rates of oesophageal adenocarcinoma and surveillance programmes.

Entities:  

Mesh:

Year:  2011        PMID: 21671079     DOI: 10.1007/s10654-011-9596-z

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  21 in total

Review 1.  Epidemiology of esophageal adenocarcinoma.

Authors:  Manuel Pera; Carlos Manterola; Oscar Vidal; Luis Grande
Journal:  J Surg Oncol       Date:  2005-12-01       Impact factor: 3.454

2.  Central adiposity and risk of Barrett's esophagus.

Authors:  Zoe R Edelstein; Diana C Farrow; Mary P Bronner; Sheldon N Rosen; Thomas L Vaughan
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

3.  Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study.

Authors:  Kee Wook Jung; Nicholas J Talley; Yvonne Romero; David A Katzka; Cathy D Schleck; Alan R Zinsmeister; Kelly T Dunagan; Lori S Lutzke; Tsung-Teh Wu; Kenneth K Wang; Mary Frederickson; Debra M Geno; G Richard Locke; Ganapathy A Prasad
Journal:  Am J Gastroenterol       Date:  2011-04-12       Impact factor: 10.864

4.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

5.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

6.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.

Authors:  M Conio; A J Cameron; Y Romero; C D Branch; C D Schleck; L J Burgart; A R Zinsmeister; L J Melton; G R Locke
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

7.  Trends in oesophageal cancer incidence and mortality in Europe.

Authors:  Cristina Bosetti; Fabio Levi; Jacques Ferlay; Werner Garavello; Franca Lucchini; Paola Bertuccio; Eva Negri; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

Review 8.  The changing epidemiology of esophageal adenocarcinoma.

Authors:  Jeffrey T Wei; NicholasJ Shaheen
Journal:  Semin Gastrointest Dis       Date:  2003-07

9.  Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006.

Authors:  D A Corley; A Kubo; T R Levin; G Block; L Habel; G Rumore; C Quesenberry; P Buffler
Journal:  Gut       Date:  2008-10-31       Impact factor: 23.059

Review 10.  Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Paresh Kamat; Sijin Wen; Jeffrey Morris; Sharmila Anandasabapathy
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330

View more
  32 in total

1.  Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

Authors:  Michael A O'Rorke; Marie M Cantwell; Christian C Abnet; And John D Brockman; Liam J Murray
Journal:  Int J Cancer       Date:  2012-03-06       Impact factor: 7.396

2.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

3.  [Esophageal precancerous lesions: early diagnosis, treatment, and preservation of quality of life].

Authors:  A Behrens; A May; H Manner; J Pohl; C Ell
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

4.  The global prevalence of Barrett's esophagus: A systematic review of the published literature.

Authors:  Inês Marques de Sá; Pedro Marcos; Prateek Sharma; Mário Dinis-Ribeiro
Journal:  United European Gastroenterol J       Date:  2020-07-06       Impact factor: 4.623

Review 5.  Optimizing the diagnosis and therapy of Barrett's esophagus.

Authors:  Juan A Muñoz-Largacha; Hiran C Fernando; Virginia R Litle
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

6.  Negative impact of sedation on esophagogastric junction evaluation during esophagogastroduodenoscopy.

Authors:  Eun Soo Kim; Ho Young Lee; Yoo Jin Lee; Bo Ram Min; Jae Hyuk Choi; Kyung Sik Park; Kwang Bum Cho; Byoung Kuk Jang; Woo Jin Chung; Jae Seok Hwang
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

7.  Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients.

Authors:  Wladyslaw Januszewicz; Wei Keith Tan; Katie Lehovsky; Irene Debiram-Beecham; Tara Nuckcheddy; Susan Moist; Sudarshan Kadri; Massimiliano di Pietro; Alex Boussioutas; Nicholas J Shaheen; David A Katzka; Evan S Dellon; Rebecca C Fitzgerald
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

8.  The risk of Barrett's esophagus associated with abdominal obesity in males and females.

Authors:  Bradley J Kendall; Graeme A Macdonald; Nicholas K Hayward; Johannes B Prins; Suzanne O'Brien; David C Whiteman
Journal:  Int J Cancer       Date:  2012-10-30       Impact factor: 7.396

9.  Upregulation of miR-494 Inhibits Cell Growth and Invasion and Induces Cell Apoptosis by Targeting Cleft Lip and Palate Transmembrane 1-Like in Esophageal Squamous Cell Carcinoma.

Authors:  Ren Zhang; Xiaonan Chen; Shengjie Zhang; Xueyan Zhang; Tong Li; Zhicai Liu; Jinwu Wang; Wenqiao Zang; Yuanyuan Wang; Yuwen Du; Guoqiang Zhao
Journal:  Dig Dis Sci       Date:  2014-12-06       Impact factor: 3.199

10.  Adherence to WCRF/AICR lifestyle recommendations for cancer prevention and the risk of Barrett's esophagus onset and evolution to esophageal adenocarcinoma: results from a pilot study in a high-risk population.

Authors:  Stefano Realdon; Alessandro Antonello; Diletta Arcidiacono; Elisa Dassie; Francesco Cavallin; Matteo Fassan; Maria Teresa Nardi; Alfredo Alberti; Massimo Rugge; Giorgio Battaglia
Journal:  Eur J Nutr       Date:  2015-07-10       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.